Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 8;8(11):107.
doi: 10.1038/s41408-018-0144-x.

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma

Shebli Atrash  1 , Myra Robinson  2 , Daniel Slaughter  2 , Amanda Aneralla  2 , Taylor Brown  1 , Jordan Robinson  1 , Ami Ndiaye  1 , Chelsea Sprouse  1 , Qing Zhang  2 , James T Symanowski  2 , Reed Friend  1 , Peter M Voorhees  1 , Saad Z Usmani  1 , Manisha Bhutani  3
Affiliations

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma

Shebli Atrash et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

S.Z.U. reports consulting for Abbvie, Amgen, BMS, Celgene, Janssen, Takeda, Sanofi, and SkylineDx; speaker’s fees for Amgen, Celgene, Janssen, and Takeda; and research funding from Amgen, Array Biopharma, BMS, Celgene, Janssen, Pharmacyclics, Sanofi, and Takeda. P.M.V. reports consulting for Celgene, Millennium Takeda, BMS, Novartis, Array Biopharma, and Janssen; research funding from GSK, Janssen, Merck, Amgen, Oncopeptides, and Acetylon. S.A. reports consulting for Celgene, and Takeda, speaker’s fees for Takeda. M.B. reports speaker’s fees for Amgen; institutional clinical trial funding from Prothena, Janssen, and MedImmune.

Figures

Fig. 1
Fig. 1
Cumulative incidence of progression for patients with smoldering multiple myeloma (N = 134). Cumulative incidence of progression was estimated with a death prior to progression considered as a competing risk event. There were 23 progression events. Median time to progression: not reached (LB of 95% CI: 4.1 years). Two-year progression-free rate: 89.4% (95% CI: 83.5–95.2%), and two-year progression rate: 10.6% (95% CI: 4.8–16.5%)
Fig. 2
Fig. 2
Cumulative incidence curves for time to progression, stratified by number of risk factors proposed in various risk models. a–d Cumulative incidence curves for time to progression, stratified by number of risk factors, estimated for each of the risk factor models: a Levine Cancer Institute model; b Evolving-Change model; c Traditional Mayo Clinic model; d Revised Mayo Clinic model. Gray’s test compared the cumulative incidence functions between risk factor groups within each model, with significance indicating a difference in the cumulative incidence distributions between the risk factor groups. Note, death was considered a competing risk event in the cumulative incidence estimation
See this image and copyright information in PMC

References

    1. Kyle RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007;356:2582–2590. doi: 10.1056/NEJMoa070389. - DOI - PubMed
    1. Dispenzieri A, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789. doi: 10.1182/blood-2007-08-108357. - DOI - PMC - PubMed
    1. Perez-Persona E, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–2592. doi: 10.1182/blood-2007-05-088443. - DOI - PubMed
    1. Lakshman A, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. doi: 10.1038/s41408-018-0077-4. - DOI - PMC - PubMed
    1. Rosinol L, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br. J. Haematol. 2003;123:631–636. doi: 10.1046/j.1365-2141.2003.04654.x. - DOI - PubMed